{"entity": "publication", "iuid": "e26b5b06030842c294ed6e3714352e77", "timestamp": "2026-08-09T05:16:32.451Z", "links": {"self": {"href": "https://publications.scilifelab.se/publication/e26b5b06030842c294ed6e3714352e77.json"}, "display": {"href": "https://publications.scilifelab.se/publication/e26b5b06030842c294ed6e3714352e77"}}, "title": "The acute effect of different NAD+ precursors included in the combined metabolic activators.", "authors": [{"family": "Li", "given": "Xiangyu", "initials": "X"}, {"family": "Yang", "given": "Hong", "initials": "H"}, {"family": "Jin", "given": "Han", "initials": "H"}, {"family": "Turkez", "given": "Hasan", "initials": "H"}, {"family": "Ozturk", "given": "Gurkan", "initials": "G"}, {"family": "Doganay", "given": "Hamdi Levent", "initials": "HL"}, {"family": "Zhang", "given": "Cheng", "initials": "C"}, {"family": "Nielsen", "given": "Jens", "initials": "J"}, {"family": "Uhl\u00e9n", "given": "Mathias", "initials": "M"}, {"family": "Bor\u00e9n", "given": "Jan", "initials": "J"}, {"family": "Mardinoglu", "given": "Adil", "initials": "A"}], "type": "controlled clinical trial", "published": "2023-08-20", "journal": {"title": "Free Radic. Biol. Med.", "issn": "1873-4596", "volume": "205", "pages": "77-89", "issn-l": "0891-5849"}, "abstract": "NAD+ and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD+ precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD+ salvage pathway is the main source for boosting the NAD+ levels with the administration of CMAs without NAD+ precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions.", "doi": "10.1016/j.freeradbiomed.2023.05.032", "pmid": "37271226", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pii", "key": "S0891-5849(23)00473-2"}], "notes": [], "created": "2023-11-27T21:44:26.698Z", "modified": "2024-01-16T13:48:32.465Z"}